UOC
CRDF icon

UBS O'Connor’s Cardiff Oncology CRDF Stock Holding History

UBS O'Connor’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150,000
Closed -$333K – 524
2024
Q2 		$333K Buy
+150,000
New +$565K 0.01% 390

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS O'Connor's CRDF Position: Q3 2024 in Review

UBS O'Connor sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 150,000 shares — an estimated $333K sold.

UBS O'Connor first reported a position in CRDF in Q2 2024 and held it in 1 quarter. The position peaked at $333K in Q2 2024. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

  • UBS O'Connor reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 150,000 Cardiff Oncology shares in Q3 2024, an estimated $333K.
  • UBS O'Connor first reported a position in Cardiff Oncology in Q2 2024 and held it in 1 quarter.
  • UBS O'Connor's Cardiff Oncology position peaked at $333K in Q2 2024.
  • 83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.